loading
Schlusskurs vom Vortag:
$1.69
Offen:
$1.7473
24-Stunden-Volumen:
50,401
Relative Volume:
0.01
Marktkapitalisierung:
$9.95M
Einnahmen:
$1.38M
Nettoeinkommen (Verlust:
$-179.05M
KGV:
-0.2949
EPS:
-6.14
Netto-Cashflow:
$-155.03M
1W Leistung:
+6.30%
1M Leistung:
-19.23%
6M Leistung:
+208.27%
1J Leistung:
-31.75%
1-Tages-Spanne:
Value
$1.73
$1.8775
1-Wochen-Bereich:
Value
$1.60
$1.8775
52-Wochen-Spanne:
Value
$0.16
$6.83

Bioxcel Therapeutics Inc Stock (BTAI) Company Profile

Name
Firmenname
Bioxcel Therapeutics Inc
Name
Telefon
203-643-8060
Name
Adresse
555 LONG WHARF DRIVE, NEW HAVEN, CT
Name
Mitarbeiter
37
Name
Twitter
@bioxcel_tx
Name
Nächster Verdiensttermin
2024-11-12
Name
Neueste SEC-Einreichungen
Name
BTAI's Discussions on Twitter

Vergleichen Sie BTAI mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
BTAI
Bioxcel Therapeutics Inc
1.82 9.95M 1.38M -179.05M -155.03M -6.14
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
489.11 124.91B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
592.40 60.05B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
600.75 35.88B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
240.12 29.83B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
255.04 24.58B 3.81B -644.79M -669.77M -6.24

Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-02-21 Herabstufung UBS Buy → Neutral
2023-08-15 Herabstufung Mizuho Buy → Neutral
2023-07-17 Herabstufung Guggenheim Buy → Neutral
2023-03-10 Herabstufung Jefferies Buy → Hold
2022-12-01 Hochstufung Goldman Sell → Neutral
2022-07-07 Eingeleitet Mizuho Buy
2022-04-06 Bestätigt BofA Securities Buy
2021-11-15 Herabstufung Goldman Neutral → Sell
2021-04-09 Eingeleitet Berenberg Buy
2021-02-01 Eingeleitet UBS Buy
2020-10-30 Eingeleitet Goldman Buy
2020-09-02 Eingeleitet Jefferies Buy
2020-08-17 Bestätigt H.C. Wainwright Buy
2020-07-08 Bestätigt H.C. Wainwright Buy
2020-06-04 Eingeleitet Guggenheim Buy
2020-04-01 Eingeleitet BofA/Merrill Buy
2020-02-26 Bestätigt H.C. Wainwright Buy
2020-01-08 Bestätigt H.C. Wainwright Buy
2019-11-12 Eingeleitet SunTrust Buy
Alle ansehen

Bioxcel Therapeutics Inc Aktie (BTAI) Neueste Nachrichten

pulisher
Apr 06, 2025

BioXcel Therapeutics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - ACCESS Newswire

Apr 06, 2025
pulisher
Apr 05, 2025

BioXcel Therapeutics stock hits 52-week low at $1.72 By Investing.com - Investing.com Canada

Apr 05, 2025
pulisher
Apr 04, 2025

BioXcel Therapeutics stock hits 52-week low at $1.72 - Investing.com

Apr 04, 2025
pulisher
Apr 04, 2025

BioXcel Therapeutics Initiates At-The-Market Equity Program - Investing.com Australia

Apr 04, 2025
pulisher
Apr 03, 2025

BioXcel Therapeutics Initiates At-The-Market Equity Program By Investing.com - Investing.com Canada

Apr 03, 2025
pulisher
Apr 03, 2025

Bioxcel Therapeutics May Offer And Sell Shares Of Common Stock Of Up To $8.1 Million From Time To Time Through CanaccordSEC Filing - MarketScreener

Apr 03, 2025
pulisher
Apr 02, 2025

ROSEN, A RANKED AND LEADING FIRM, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BTAI - AsiaOne

Apr 02, 2025
pulisher
Mar 29, 2025

BioXcel Therapeutics, Inc. (BTAI) Reports Q4 Loss, Tops Revenue Estimates - MSN

Mar 29, 2025
pulisher
Mar 29, 2025

BioXcel Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Mar 29, 2025
pulisher
Mar 28, 2025

BioXcel Therapeutics Advances Clinical Trials and Reduces Losses - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

BioXcel Therapeutics Inc. (BTAI) reports earnings - Quartz

Mar 28, 2025
pulisher
Mar 28, 2025

BioXcel Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 28, 2025
pulisher
Mar 27, 2025

BioXcel Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 27, 2025
pulisher
Mar 27, 2025

BioXcel Therapeutics, Inc. Q4 Loss Declines - Nasdaq

Mar 27, 2025
pulisher
Mar 27, 2025

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024 - GlobeNewswire

Mar 27, 2025
pulisher
Mar 26, 2025

Dementia Associated With Alzheimer’s Disease Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail

Mar 26, 2025
pulisher
Mar 22, 2025

BioXcel Therapeutics faces potential Nasdaq delisting By Investing.com - Investing.com India

Mar 22, 2025
pulisher
Mar 22, 2025

BioXcel Therapeutics (NASDAQ:BTAI) Upgraded at RODMAN&RENSHAW - Defense World

Mar 22, 2025
pulisher
Mar 21, 2025

BioXcel Therapeutics faces potential Nasdaq delisting - Investing.com

Mar 21, 2025
pulisher
Mar 21, 2025

BIOXCEL THERAPEUTICS INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com

Mar 21, 2025
pulisher
Mar 21, 2025

BioXcel Therapeutics reports progress in Phase 3 trial By Investing.com - Investing.com South Africa

Mar 21, 2025
pulisher
Mar 21, 2025

BioXcel Therapeutics reports progress in Phase 3 trial - Investing.com India

Mar 21, 2025
pulisher
Mar 19, 2025

Rodman & Renshaw Initiates Coverage of BioXcel Therapeutics (BTAI) with Buy Recommendation - Nasdaq

Mar 19, 2025
pulisher
Mar 19, 2025

Tap Billion-Dollar AI Opportunity in Oncology: Stocks in the Spotlight - Nasdaq

Mar 19, 2025
pulisher
Mar 11, 2025

BioXcel Therapeutics boosts cash to $35M for Phase 3 trial - Investing.com Australia

Mar 11, 2025
pulisher
Mar 11, 2025

BioXcel Therapeutics boosts cash to $35M for Phase 3 trial By Investing.com - Investing.com South Africa

Mar 11, 2025
pulisher
Mar 11, 2025

BioXcel Therapeutics: Topline Data Expected In H2 Of 2025 To Support Potential SNDA Submission For Label Expansion Of Igalmi In Home Setting - MarketScreener

Mar 11, 2025
pulisher
Mar 11, 2025

BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia - GlobeNewswire

Mar 11, 2025
pulisher
Mar 11, 2025

BioXcel's $35M Funding Boost Powers Breakthrough At-Home Mental Health Treatment Trial - StockTitan

Mar 11, 2025
pulisher
Mar 10, 2025

Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance

Mar 10, 2025
pulisher
Mar 09, 2025

Why BioXcel Therapeutics, Inc. (BTAI) Soared Last Week - MSN

Mar 09, 2025
pulisher
Mar 09, 2025

10 Micro-, Small-Cap Firms Were Last Week’s Top Performers - Insider Monkey

Mar 09, 2025
pulisher
Mar 08, 2025

BioXcel Therapeutics, Inc. (BTAI) May Report Negative Earnings: Know the Trend Ahead of Q4 Release - MSN

Mar 08, 2025
pulisher
Mar 07, 2025

BioXcel Therapeutics reaches 33% enrollment in trial By Investing.com - Investing.com Australia

Mar 07, 2025
pulisher
Mar 07, 2025

BioXcel Therapeutics reaches 33% enrollment in trial - Investing.com

Mar 07, 2025
pulisher
Mar 07, 2025

BioXcel Therapeutics Reports 33% Enrollment in SERENITY At-Home Trial for IGALMI® Label Expansion, Topline Data Expected in 2025 - Nasdaq

Mar 07, 2025
pulisher
Mar 07, 2025

BioXcel Therapeutics announces 33% enrollment in SERENTIY at-home Phase 3 trial - TipRanks

Mar 07, 2025
pulisher
Mar 07, 2025

BioXcel Therapeutics Announces 33% Enrollment in SERENITY - GlobeNewswire

Mar 07, 2025
pulisher
Mar 07, 2025

Could This Be the First FDA-Approved At-Home Treatment for Bipolar and Schizophrenia Agitation? - StockTitan

Mar 07, 2025

Finanzdaten der Bioxcel Therapeutics Inc-Aktie (BTAI)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.27
price up icon 0.35%
$67.24
price down icon 2.81%
$31.69
price down icon 0.93%
$33.23
price down icon 0.81%
$114.98
price down icon 0.20%
biotechnology ONC
$253.97
price up icon 0.51%
Kapitalisierung:     |  Volumen (24h):